|1.||Carretero, Oscar A: 21 articles (10/2015 - 12/2003)|
|2.||Rhaleb, Nour-Eddine: 20 articles (10/2015 - 12/2003)|
|3.||Yang, Xiao-Ping: 11 articles (05/2015 - 02/2004)|
|4.||Yang, Fang: 11 articles (08/2014 - 02/2004)|
|5.||Liao, Tang-Dong: 10 articles (10/2015 - 11/2004)|
|6.||Peng, Hongmei: 8 articles (10/2013 - 12/2003)|
|7.||Wdzieczak-Bakala, Joanna: 7 articles (01/2013 - 02/2006)|
|8.||Xu, Hong: 6 articles (08/2014 - 01/2012)|
|9.||Liu, Jian-Miao: 6 articles (04/2010 - 02/2006)|
|10.||Sturrock, Edward D: 5 articles (01/2015 - 09/2012)|
02/01/2004 - "We concluded that Ac-SDKP has an anti-inflammatory effect in HF that may contribute to its antifibrotic effect; however, this decrease in fibrosis without changes in LVH was not accompanied by an improvement in cardiac function."
02/01/2010 - "The aim of the present study was to evaluate the effect of Ac-SDKP on cardiac systolic and diastolic function, and interstitial and perivascular fibrosis in the heart of diabetic rats.Diabetes"
01/01/2015 - "N-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice."
01/01/2014 - "N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes."
01/01/2014 - "Conventional ACE inhibitor plus AcSDKP ameliorated kidney fibrosis and inhibited EndMT compared to therapy with the ACE inhibitor alone in diabetic CD-1 mice. "
12/01/2012 - "Ac-SDKP-treated MRL/lpr mice showed reduced proteinuria and improved renal function compared with vehicle-treated controls. "
02/01/2011 - "Loss of nephrin reportedly causes excess urinary protein excretion; therefore, we determined whether Ac-SDKP inhibits proteinuria by restoring nephrin expression in the glomerulus of hypertensive mice. "
06/01/2006 - "Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study."
03/01/2006 - "Fourteen days after the induction of anti-glomerular basement membrane nephritis, the rats were treated subcutaneously with Ac-SDKP at a dose of 1 mg/kg per d for 4 wk. Treatment with Ac-SDKP significantly improved proteinuria and renal dysfunction, including increased plasma blood urea nitrogen and creatinine levels and decreased creatinine clearance. "
06/01/2006 - "The purpose of this study was to assess patients' and physicians' compliance with ACE inhibitor treatment, by measuring an endogenous biomarker of ACE inhibition, urinary N-acetyl-Ser-Asp-Lys-Pro (AcSDKP), in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) trial, which compared ramipril (1.25 mg o.d.) with placebo in 4,912 patients with type 2 diabetes and microalbuminuria/proteinuria. "
10/01/2015 - "Conversely, in SS13BN rats, both doses of Ac-SDKP prevented HS-induced renal damage and albuminuria."
10/01/2015 - "Only the high dose of Ac-SDKP attenuated HS-induced albuminuria. "
10/01/2015 - "Interestingly, in SS13BN rats, Ac-SDKP prevented albuminuria induced by HS (HS+vehicle, 44±8 versus HS+low Ac-SDKP, 24±3 or HS+high Ac-SDKP, 8±1 mg/24 h; P<0.05), whereas in SS rats, only high Ac-SDKP dose significantly attenuated albuminuria (HS+vehicle, 94±10 versus HS+high Ac-SDKP, 57±7 mg/24 h; P<0.05). "
02/01/2010 - "We concluded that Ac-SDKP greatly attenuates albuminuria and renal fibrosis and improves renal function in rats with 5/6Nx. "
02/01/2011 - "Thus, we hypothesized that Ac-SDKP has renal protective effects on deoxycorticosterone acetate (DOCA)-salt hypertensive mice, decreasing inflammatory cell infiltration, matrix deposition and albuminuria. "
05/15/2015 - "It has also been reported that Ac-SDKP ameliorates lupus nephritis in mice. "
12/01/2012 - "Ac-SDKP ameliorates the progression of lupus nephritis in MRL/lpr mice."
12/01/2012 - "This study examined the effects of Ac-SDKP on the progression of lupus nephritis (LN). "
05/15/2015 - "We hypothesize that Ac-SDKP prevents lupus nephritis in mice by decreasing complement C5-9, proinflammatory cytokines, and immune cell infiltration. "
|5.||Hypertension (High Blood Pressure)
01/01/2015 - "First, the level of Ac- SDKP in plasma and tissues is reduced in some cardiovascular pathologies such as hypertension. "
01/01/2014 - "We induced hypertension in rats by infusing AngII either alone or combined with Ac-SDKP for 3 weeks. "
02/01/2010 - "However, it is unknown whether Ac-SDKP can prevent or reverse renal injury and dysfunction in hypertension. "
02/01/2010 - "N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research."
09/01/2008 - "These data indicate that in ANG II-induced hypertension Ac-SDKP has an aortic antifibrotic effect. "
|1.||Transforming Growth Factor beta (TGF-beta)
|8.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|9.||Connective Tissue Growth Factor
|3.||Infusion Pumps (Infusion Pump)